CMN Weekly (30 May 2025) - Your Weekly CRISPR...
CMN Weekly
May. 30, 2025
CRISPR Therapeutics AG
CRISPR Therapeutics AG
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Cardiovascular Disease or Calcific Aortic Valve Stenosis, (ACTRN12623001095651p)
Sponsors:
CRISPR Therapeutics AG
Sponsors:
CRISPR Therapeutics AG
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated
Sponsors:
Vertex Pharmaceuticals Incorporated
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
